Overview
Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2022-07-01
2022-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Research objective: To explore the safety and dose exploration of Remimazolam Tosilate for Injection for induction and maintenance of general anesthesia in elective short-term surgery in adults. Main research indicators:(1)Success rate of sedation during induction and maintenance of general anesthesia with remazolam tosylate;(2)The incidence and severity of hypotension in the induction and maintenance phases Study design: Multi-center, randomized, double-blind clinical study. Subject population: patients undergoing elective short-term surgery. Research data collection period: The subject signs the consent form until discharge or death in the hospital or withdrawal from the research. Number of research centers/sample size: It is planned to enroll 600 patients from 11 hospitals. Research process: The researchers will include patients who meet the enrollment criteria and agree to participate in the investigation of the support laryngoscope surgery and minor head and neck surgery patients from the elective surgery patients.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Tongji Hospital
Criteria
Inclusion Criteria:1. ASA Ⅰ-Ⅲ grade;
2. age 18-65 years old;
3. gender is not limited;
4. planned elective support laryngoscope surgery (glottic polypectomy under support
laryngoscope, epiglottic cyst excision under support laryngoscope, benign laryngeal
under support laryngoscope Lesion resection), endoscopic septoplasty, endoscopic
tympanoplasty, endoscopic middle ear tube insertion, nasopharyngoplasty, head and neck
benign mass resection for general anesthesia intubation patients;
5. operation time No more than 90min.
Exclusion Criteria:
- Emergency surgery;
1. abnormal renal function (urea nitrogen ≥1.5×ULN, blood creatinine greater than the
upper limit of normal);
2. abnormal liver function;
3. hypovolemia, shock or coma;
4. suffering from mental illness and long-term use of psychotropic drugs;
5. cognition Dysfunction;
6. those who are allergic to or contraindicated to benzodiazepines and their drug
components; pregnant or lactating female patients;
7. have a history of drug dependence;
8. have used other sedatives in the past week;
9. have been a subject within the past 3 months Participated in drug clinical trials